| Systematic (IUPAC) name | |
|---|---|
| (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 250672-65-2 |
| ATC code | ? |
| PubChem | CID 10466404 |
| Chemical data | |
| Formula | C14H17N2O |
| Mol. mass | 229.297 g/mol |
| SMILES | eMolecules & PubChem |
| |
|
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine or lucigenol) is a tryptamine derivative that is a hallucinogenic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine derived hallucinogen DOI, and has two enantiomers, with only the (R)-enantiomer being active.[1]
The binding affinity for 5-HT2A receptor is 13 +/- 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six to eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[2][unreliable source?]
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)